Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York, NY, shares some insights into challenges and unanswered questions in acute myeloid leukemia (AML), including the challenge of treating patients with TP53-mutated disease, and the role of maintenance therapy. Prof. Konopleva also highlights the need to better define the role of measurable residual disease (MRD) in AML, and the potential use of immunotherapeutic agents in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.